Prophylactic effect of tranexamic acid capsule in controlling epistaxis

Evaluation of prophylactic effect of tranexamic acid capsule on nasal hemorrhage in patients with epistaxis

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180425039418N7

Enrollment

100

Registered

2019-07-10

Start date

2018-12-22

Completion date

Unknown

Last updated

2019-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epistaxis. Epistaxis

Interventions

Intervention 1: Intervention group: For 50 patients, drops of NaCl and vitamin A ointment with 500 mg tranexamic acid were administered every 8 hours a week. Intervention 2: Control group: For 50 pati

Eligibility

Sex/Gender

All

Age

15 Years to 85 Years

Inclusion criteria

Inclusion criteria: Insensitivity to the drugs used in the study Satisfaction to enter the study

Exclusion criteria

Exclusion criteria: Patients with seizure, arterial or venous thrombosis, leukemia, lymphoma, polycythemia vera, pregnant women Patients who have taken anticoagulants, anti-platelets and even aspirin

Design outcomes

Primary

Measure	Time frame
Patient satisfaction from treatment based on questionnaire. Timepoint: Every week from the start of treatment and up to one month after treatment. Method of measurement: questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Gholamali Dashti Khudaki

Zahedan University of Medical Sciences

mohammad.ghenaat71@gmail.com+98 54 3329 5715

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026